Recapitulation of Antimalarial Drugs use in the Prevention and Treatment of Novel Coronavirus Disease
Abstract
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused Coronavirus pandemic (COVID- 19). Repurposing of antimalarial drugs as a potential treatment option for hospitalized, non-hospitalized as well for prevention against SARS CoV-2 have been researched as potential COVID-19 treatments, with some moving into clinical trials. This review article revisits the evidence and draws comparison regarding their safety and efficacy.
References
Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges. International journal of antimicrobial agents. 2020; 55: 1-9.
World Health Organization. COVID 19 Public Health Emergency of International Concern (PHEIC). Global research and innovation forum: towards a research roadmap. Available at: https://www.who.int/publications/ m/item/covid-19-public-health-emergency-of- international-concern-(pheic)-global-research-and- innovation-forum.
World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. Geneva, Switzerland. [Updated on 19th August 2020, Accessed on 19th August 2020]. Available at: https://covid19.who.int/.
Hassan SA, Sheikh FN, Jamal S, Ezeh JK, Akhtar A. Coronavirus (COVID-19): a review of clinical features, diagnosis, and treatment. Cureus. 2020; 12: e7355-60.
Nicola M, O'Neill N, Sohrabi C, Khan M, Agha M, Agha R. Evidence based management guideline for the COVID-19 pandemic-review article. International Journal of Surgery. 2020: 77: 206-16.
Lythgoe MP, Middleton P. Ongoing clinical trials for the management of the COVID-19 pandemic. Trends in Pharmacological Sciences. 2020; 41: 363-82.
Qayyumi B, Singh A, Tuljapurkar V, Chaturvedi P. Management of COVID-19: A brief overview of the various treatment strategies. Cancer Research, Statistics, and Treatment. 2020; 3: 233-43.
Alijotas-Reig J, Esteve-Valverde E, Belizna C, Selva- O'Callaghan A, Pardos-Gea J, Quintana A, et al. Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review. Autoimmunity Reviews. May 2020; 19: 102569.
Shah S, Das S, Jain A, Misra DP, Negi VS. A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19). International Journal of Rheumatic Diseases. 202; 23: 613- 9.
Horby P, Landray M. Statement from the Chief Investigators of the Randomized Evaluation of COVID-19 therapy (Recovery) trial on hydroxychloroquine. [Updated 5th Jun 2020, Accessed 21st Aug 2020]. Available at: https://www.recoverytrial.net/files/hcq-recovery- statement-050620-final-002.pdf.
Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell discovery. 2020; 6: 1-4.
Zhou D, Dai SM, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. Journal of Antimicrobial Chemotherapy. 2020; 75: 1667-70.
Al-Rawi H, Meggitt SJ, Williams FM, Wahie S. Steady-state pharmacokinetics of hydroxychloroquine in patients with cutaneous lupus erythematosus. Lupus. 2018; 27: 847-52.
Juurlink DN. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection. CMAJ. 2020; 192: e450-3.
Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Bioscience trends. 2020; 14: 72-3.
Wozniacka A, Lesiak A, Narbutt J, McCauliffe DP, Sysa- Jedrzejowska A. Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients. Lupus. 2006; 15: 268-75.
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell research. 2020; 30: 269-71.
Yao X, Ye F,Zhang M,Cui C, Huang B, Niu P, et al. Invitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases. 2020; 71: 732-9.
Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. Journal of critical care. 2020; 57: 279-83.
National Institute of Health. Clinical Trials Registry, National Library of Medicine. USA. [Updated 10th Aug 2020, Accessed on 21st Aug 2020]. Available at: https://clinicaltrials.gov/ct2/results?cond=hydroxychloroq uine+AND+COVID&Search=Apply&age_v=&gndr=&type=I ntr&rslt=.
Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid- 19. New England Journal of Medicine. 2020; 383: 517-25.
Post-exposure Prophylaxis / Preemptive Therapy for SARS- Coronavirus-2 (COVID-19 PEP). ClinicalTrials.gov Identifier: NCT04308668. Available at: https://clinicaltrials.gov/ct2/show/NCT04308668.
A5395: A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy Of Hydroxychloroquine And Azithromycin To Prevent Hospitalization Or Death In Persons With COVID-19. Available at: https://actgnetwork.org/studies/a5395/.
The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine) (PATCH). ClinicalTrials.gov Identifier: NCT04329923. [Accessed on 24th Aug 2020]. Available at: https://www.clinicaltrials.gov/ct2/ show/NCT04329923.
Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19). ClinicalTrials.gov Identifier: NCT04318444. [Accessed on 24th Aug 2020]. Available at: https://www.clinicaltrials.gov/ct2/ show/NCT04318444.
Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP) (HCQPreP). ClinicalTrials.gov Identifier: NCT04363450. [Accessed on 24th Aug 2020]. Available at: https://www.clinicaltrials.gov/ct2/show/NCT04363450.
World Health Organization. Solidarity clinical trial for COVID-19 treatments. WHO, Geneva. [Updated on 5th Jul 2020, Accessed on 21st Aug 2020]. Available at: https://www.who.int/emergencies/diseases/novel- coronavirus-2019/global-research-on-novel-coronavirus- 2019-ncov/solidarity-clinical-trial-for-covid-19- treatments.
Mehra MR, Desai SS, Ruschitzka F, Patel AN. [RETRACTED] Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. The Lancet. 2020.
Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LC, Veiga VC, Avezum A, et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. New England Journal of Medicine. 2020.
Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. MedRxiv. 2020.
Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients with COVID-19: an open- label, randomized, controlled trial. MedRxiv. Apr 2020.
Gautret P, Lagier JC, Parola P, Meddeb L, Mailhe M, Doudier B, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non- randomized clinical trial. International journal of antimicrobial agents. 2020; 56: 1-6.
Cennimo DJ. What is the role of hydroxychloroquine plus azithromycin in the treatment of coronavirus disease 2019? [Internet]. Medscape. [Unpdated on 10 Aug 2020, Accessed on 22 Aug 2020]. Available at: https://www.medscape.com/answers/2500114- 197472/what-is-the-role-of-hydroxychloroquine-plus- azithromycin-in-the-treatment-of-coronavirus-disease- 2019-covid-19.
Molina JM, Delaugerre C, Le Goff J, Mela-Lima B, Ponscarme D, Goldwirt L, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect. 2020; 50: 384-9.
Skipper CP, Pastick KA, Engen NW, Bangdiwala AS, Abassi M, Lofgren SM, et al. Hydroxychloroquine in non-hospitalized adults with early COVID-19: a randomized trial. Annals of internal medicine. 2020.
FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems. FDA, United States. [Updated on 1st July 2020, Accessed on 25th Aug 2020]. Available at: https://www.fda.gov/drugs/drug- safety-and-availability/fda-cautions-against-use- hydroxychloroquine-or-chloroquine-covid-19-outside- hospital-setting-or.
White NJ. Cardiotoxicity of antimalarial drugs. The Lancet infectious diseases. 2007; 7: 549-58.
Simpson TF, Kovacs RJ, Stecker EC. Ventricular Arrhythmia risk due to hydroxychloroquine-azithromycin treatment for covid-19. American College of Cardiology; Cardiac Magazine. [Accessed on 24th Aug 2020]. Available at: https://www.acc.org/latest-in- cardiology/articles/2020/03/27/14/00/ventricular- arrhythmia-risk-due-to-hydroxychloroquine-azithromycin- treatment-for-covid-19.
Borba M, de Almeida Val F, Sampaio VS, Alexandre MA, Melo GC, Brito M, et al. Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study). MedRxiv.2020.
Lane JC, Weaver J, Kostka K, Duarte-Salles T, Abrahao MT, Alghoul H, et al. Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide- spread use for COVID-19: a multinational, network cohort and self-controlled case series study. medRxiv. 2020.
